Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis
• A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory P...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Torasawa, Masahiro [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation - Garrote, Pedro J. ELSEVIER, 2019, journal of the International Association for the Study of Lung Cancer, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:167 ; year:2022 ; pages:49-57 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.lungcan.2022.03.020 |
|---|
| Katalog-ID: |
ELV057515972 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV057515972 | ||
| 003 | DE-627 | ||
| 005 | 20230625002238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220808s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2022.03.020 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001751.pica |
| 035 | |a (DE-627)ELV057515972 | ||
| 035 | |a (ELSEVIER)S0169-5002(22)00389-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Torasawa, Masahiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis |
| 264 | 1 | |c 2022 | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory PD-L1-positive NSCLC patients. | ||
| 650 | 7 | |a FDA |2 Elsevier | |
| 650 | 7 | |a PR |2 Elsevier | |
| 650 | 7 | |a PS |2 Elsevier | |
| 650 | 7 | |a NSCLC |2 Elsevier | |
| 650 | 7 | |a OS |2 Elsevier | |
| 650 | 7 | |a IHC |2 Elsevier | |
| 650 | 7 | |a CI |2 Elsevier | |
| 650 | 7 | |a DOR |2 Elsevier | |
| 650 | 7 | |a IgG4 |2 Elsevier | |
| 650 | 7 | |a HR |2 Elsevier | |
| 650 | 7 | |a SMD |2 Elsevier | |
| 650 | 7 | |a ICI |2 Elsevier | |
| 650 | 7 | |a ORR |2 Elsevier | |
| 650 | 7 | |a CR |2 Elsevier | |
| 650 | 7 | |a NLR |2 Elsevier | |
| 650 | 7 | |a ECOG |2 Elsevier | |
| 650 | 7 | |a TPS |2 Elsevier | |
| 650 | 7 | |a PD-L1 |2 Elsevier | |
| 650 | 7 | |a PFS |2 Elsevier | |
| 650 | 7 | |a PD-1 |2 Elsevier | |
| 700 | 1 | |a Yoshida, Tatsuya |4 oth | |
| 700 | 1 | |a Yagishita, Shigehiro |4 oth | |
| 700 | 1 | |a Shimoda, Yukiko |4 oth | |
| 700 | 1 | |a Shirasawa, Masayuki |4 oth | |
| 700 | 1 | |a Matsumoto, Yuji |4 oth | |
| 700 | 1 | |a Masuda, Ken |4 oth | |
| 700 | 1 | |a Shinno, Yuki |4 oth | |
| 700 | 1 | |a Okuma, Yusuke |4 oth | |
| 700 | 1 | |a Goto, Yasushi |4 oth | |
| 700 | 1 | |a Horinouchi, Hidehito |4 oth | |
| 700 | 1 | |a Yamamoto, Noboru |4 oth | |
| 700 | 1 | |a Takahashi, Kazuhisa |4 oth | |
| 700 | 1 | |a Ohe, Yuichiro |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Garrote, Pedro J. ELSEVIER |t Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |d 2019 |d journal of the International Association for the Study of Lung Cancer |g Amsterdam [u.a.] |w (DE-627)ELV002331438 |
| 773 | 1 | 8 | |g volume:167 |g year:2022 |g pages:49-57 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.lungcan.2022.03.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 951 | |a AR | ||
| 952 | |d 167 |j 2022 |h 49-57 |g 9 | ||
| author_variant |
m t mt |
|---|---|
| matchkey_str |
torasawamasahiroyoshidatatsuyayagishitas:2022----:iouavrupmrlzmbnrvosyraeavnennmlcllncneptetarp |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
10.1016/j.lungcan.2022.03.020 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001751.pica (DE-627)ELV057515972 (ELSEVIER)S0169-5002(22)00389-0 DE-627 ger DE-627 rakwb eng Torasawa, Masahiro verfasserin aut Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis 2022 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory PD-L1-positive NSCLC patients. FDA Elsevier PR Elsevier PS Elsevier NSCLC Elsevier OS Elsevier IHC Elsevier CI Elsevier DOR Elsevier IgG4 Elsevier HR Elsevier SMD Elsevier ICI Elsevier ORR Elsevier CR Elsevier NLR Elsevier ECOG Elsevier TPS Elsevier PD-L1 Elsevier PFS Elsevier PD-1 Elsevier Yoshida, Tatsuya oth Yagishita, Shigehiro oth Shimoda, Yukiko oth Shirasawa, Masayuki oth Matsumoto, Yuji oth Masuda, Ken oth Shinno, Yuki oth Okuma, Yusuke oth Goto, Yasushi oth Horinouchi, Hidehito oth Yamamoto, Noboru oth Takahashi, Kazuhisa oth Ohe, Yuichiro oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:167 year:2022 pages:49-57 extent:9 https://doi.org/10.1016/j.lungcan.2022.03.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 167 2022 49-57 9 |
| spelling |
10.1016/j.lungcan.2022.03.020 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001751.pica (DE-627)ELV057515972 (ELSEVIER)S0169-5002(22)00389-0 DE-627 ger DE-627 rakwb eng Torasawa, Masahiro verfasserin aut Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis 2022 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory PD-L1-positive NSCLC patients. FDA Elsevier PR Elsevier PS Elsevier NSCLC Elsevier OS Elsevier IHC Elsevier CI Elsevier DOR Elsevier IgG4 Elsevier HR Elsevier SMD Elsevier ICI Elsevier ORR Elsevier CR Elsevier NLR Elsevier ECOG Elsevier TPS Elsevier PD-L1 Elsevier PFS Elsevier PD-1 Elsevier Yoshida, Tatsuya oth Yagishita, Shigehiro oth Shimoda, Yukiko oth Shirasawa, Masayuki oth Matsumoto, Yuji oth Masuda, Ken oth Shinno, Yuki oth Okuma, Yusuke oth Goto, Yasushi oth Horinouchi, Hidehito oth Yamamoto, Noboru oth Takahashi, Kazuhisa oth Ohe, Yuichiro oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:167 year:2022 pages:49-57 extent:9 https://doi.org/10.1016/j.lungcan.2022.03.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 167 2022 49-57 9 |
| allfields_unstemmed |
10.1016/j.lungcan.2022.03.020 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001751.pica (DE-627)ELV057515972 (ELSEVIER)S0169-5002(22)00389-0 DE-627 ger DE-627 rakwb eng Torasawa, Masahiro verfasserin aut Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis 2022 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory PD-L1-positive NSCLC patients. FDA Elsevier PR Elsevier PS Elsevier NSCLC Elsevier OS Elsevier IHC Elsevier CI Elsevier DOR Elsevier IgG4 Elsevier HR Elsevier SMD Elsevier ICI Elsevier ORR Elsevier CR Elsevier NLR Elsevier ECOG Elsevier TPS Elsevier PD-L1 Elsevier PFS Elsevier PD-1 Elsevier Yoshida, Tatsuya oth Yagishita, Shigehiro oth Shimoda, Yukiko oth Shirasawa, Masayuki oth Matsumoto, Yuji oth Masuda, Ken oth Shinno, Yuki oth Okuma, Yusuke oth Goto, Yasushi oth Horinouchi, Hidehito oth Yamamoto, Noboru oth Takahashi, Kazuhisa oth Ohe, Yuichiro oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:167 year:2022 pages:49-57 extent:9 https://doi.org/10.1016/j.lungcan.2022.03.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 167 2022 49-57 9 |
| allfieldsGer |
10.1016/j.lungcan.2022.03.020 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001751.pica (DE-627)ELV057515972 (ELSEVIER)S0169-5002(22)00389-0 DE-627 ger DE-627 rakwb eng Torasawa, Masahiro verfasserin aut Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis 2022 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory PD-L1-positive NSCLC patients. FDA Elsevier PR Elsevier PS Elsevier NSCLC Elsevier OS Elsevier IHC Elsevier CI Elsevier DOR Elsevier IgG4 Elsevier HR Elsevier SMD Elsevier ICI Elsevier ORR Elsevier CR Elsevier NLR Elsevier ECOG Elsevier TPS Elsevier PD-L1 Elsevier PFS Elsevier PD-1 Elsevier Yoshida, Tatsuya oth Yagishita, Shigehiro oth Shimoda, Yukiko oth Shirasawa, Masayuki oth Matsumoto, Yuji oth Masuda, Ken oth Shinno, Yuki oth Okuma, Yusuke oth Goto, Yasushi oth Horinouchi, Hidehito oth Yamamoto, Noboru oth Takahashi, Kazuhisa oth Ohe, Yuichiro oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:167 year:2022 pages:49-57 extent:9 https://doi.org/10.1016/j.lungcan.2022.03.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 167 2022 49-57 9 |
| allfieldsSound |
10.1016/j.lungcan.2022.03.020 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001751.pica (DE-627)ELV057515972 (ELSEVIER)S0169-5002(22)00389-0 DE-627 ger DE-627 rakwb eng Torasawa, Masahiro verfasserin aut Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis 2022 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory PD-L1-positive NSCLC patients. FDA Elsevier PR Elsevier PS Elsevier NSCLC Elsevier OS Elsevier IHC Elsevier CI Elsevier DOR Elsevier IgG4 Elsevier HR Elsevier SMD Elsevier ICI Elsevier ORR Elsevier CR Elsevier NLR Elsevier ECOG Elsevier TPS Elsevier PD-L1 Elsevier PFS Elsevier PD-1 Elsevier Yoshida, Tatsuya oth Yagishita, Shigehiro oth Shimoda, Yukiko oth Shirasawa, Masayuki oth Matsumoto, Yuji oth Masuda, Ken oth Shinno, Yuki oth Okuma, Yusuke oth Goto, Yasushi oth Horinouchi, Hidehito oth Yamamoto, Noboru oth Takahashi, Kazuhisa oth Ohe, Yuichiro oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:167 year:2022 pages:49-57 extent:9 https://doi.org/10.1016/j.lungcan.2022.03.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 167 2022 49-57 9 |
| language |
English |
| source |
Enthalten in Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation Amsterdam [u.a.] volume:167 year:2022 pages:49-57 extent:9 |
| sourceStr |
Enthalten in Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation Amsterdam [u.a.] volume:167 year:2022 pages:49-57 extent:9 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
FDA PR PS NSCLC OS IHC CI DOR IgG4 HR SMD ICI ORR CR NLR ECOG TPS PD-L1 PFS PD-1 |
| isfreeaccess_bool |
false |
| container_title |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| authorswithroles_txt_mv |
Torasawa, Masahiro @@aut@@ Yoshida, Tatsuya @@oth@@ Yagishita, Shigehiro @@oth@@ Shimoda, Yukiko @@oth@@ Shirasawa, Masayuki @@oth@@ Matsumoto, Yuji @@oth@@ Masuda, Ken @@oth@@ Shinno, Yuki @@oth@@ Okuma, Yusuke @@oth@@ Goto, Yasushi @@oth@@ Horinouchi, Hidehito @@oth@@ Yamamoto, Noboru @@oth@@ Takahashi, Kazuhisa @@oth@@ Ohe, Yuichiro @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV002331438 |
| id |
ELV057515972 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV057515972</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625002238.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.lungcan.2022.03.020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001751.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV057515972</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0169-5002(22)00389-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Torasawa, Masahiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory PD-L1-positive NSCLC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FDA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NSCLC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">OS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IHC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DOR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IgG4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SMD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ICI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ORR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NLR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ECOG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TPS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD-L1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PFS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD-1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yoshida, Tatsuya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yagishita, Shigehiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shimoda, Yukiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shirasawa, Masayuki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsumoto, Yuji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Masuda, Ken</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shinno, Yuki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Okuma, Yusuke</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goto, Yasushi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Horinouchi, Hidehito</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamamoto, Noboru</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takahashi, Kazuhisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohe, Yuichiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Garrote, Pedro J. ELSEVIER</subfield><subfield code="t">Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation</subfield><subfield code="d">2019</subfield><subfield code="d">journal of the International Association for the Study of Lung Cancer</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV002331438</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:167</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:49-57</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.lungcan.2022.03.020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">167</subfield><subfield code="j">2022</subfield><subfield code="h">49-57</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| author |
Torasawa, Masahiro |
| spellingShingle |
Torasawa, Masahiro Elsevier FDA Elsevier PR Elsevier PS Elsevier NSCLC Elsevier OS Elsevier IHC Elsevier CI Elsevier DOR Elsevier IgG4 Elsevier HR Elsevier SMD Elsevier ICI Elsevier ORR Elsevier CR Elsevier NLR Elsevier ECOG Elsevier TPS Elsevier PD-L1 Elsevier PFS Elsevier PD-1 Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis |
| authorStr |
Torasawa, Masahiro |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV002331438 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis FDA Elsevier PR Elsevier PS Elsevier NSCLC Elsevier OS Elsevier IHC Elsevier CI Elsevier DOR Elsevier IgG4 Elsevier HR Elsevier SMD Elsevier ICI Elsevier ORR Elsevier CR Elsevier NLR Elsevier ECOG Elsevier TPS Elsevier PD-L1 Elsevier PFS Elsevier PD-1 Elsevier |
| topic |
Elsevier FDA Elsevier PR Elsevier PS Elsevier NSCLC Elsevier OS Elsevier IHC Elsevier CI Elsevier DOR Elsevier IgG4 Elsevier HR Elsevier SMD Elsevier ICI Elsevier ORR Elsevier CR Elsevier NLR Elsevier ECOG Elsevier TPS Elsevier PD-L1 Elsevier PFS Elsevier PD-1 |
| topic_unstemmed |
Elsevier FDA Elsevier PR Elsevier PS Elsevier NSCLC Elsevier OS Elsevier IHC Elsevier CI Elsevier DOR Elsevier IgG4 Elsevier HR Elsevier SMD Elsevier ICI Elsevier ORR Elsevier CR Elsevier NLR Elsevier ECOG Elsevier TPS Elsevier PD-L1 Elsevier PFS Elsevier PD-1 |
| topic_browse |
Elsevier FDA Elsevier PR Elsevier PS Elsevier NSCLC Elsevier OS Elsevier IHC Elsevier CI Elsevier DOR Elsevier IgG4 Elsevier HR Elsevier SMD Elsevier ICI Elsevier ORR Elsevier CR Elsevier NLR Elsevier ECOG Elsevier TPS Elsevier PD-L1 Elsevier PFS Elsevier PD-1 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
t y ty s y sy y s ys m s ms y m ym k m km y s ys y o yo y g yg h h hh n y ny k t kt y o yo |
| hierarchy_parent_title |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| hierarchy_parent_id |
ELV002331438 |
| hierarchy_top_title |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV002331438 |
| title |
Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis |
| ctrlnum |
(DE-627)ELV057515972 (ELSEVIER)S0169-5002(22)00389-0 |
| title_full |
Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis |
| author_sort |
Torasawa, Masahiro |
| journal |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| journalStr |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
49 |
| author_browse |
Torasawa, Masahiro |
| container_volume |
167 |
| physical |
9 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Torasawa, Masahiro |
| doi_str_mv |
10.1016/j.lungcan.2022.03.020 |
| title_sort |
nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: a propensity-matched real-world analysis |
| title_auth |
Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis |
| abstract |
• A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory PD-L1-positive NSCLC patients. |
| abstractGer |
• A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory PD-L1-positive NSCLC patients. |
| abstract_unstemmed |
• A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory PD-L1-positive NSCLC patients. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis |
| url |
https://doi.org/10.1016/j.lungcan.2022.03.020 |
| remote_bool |
true |
| author2 |
Yoshida, Tatsuya Yagishita, Shigehiro Shimoda, Yukiko Shirasawa, Masayuki Matsumoto, Yuji Masuda, Ken Shinno, Yuki Okuma, Yusuke Goto, Yasushi Horinouchi, Hidehito Yamamoto, Noboru Takahashi, Kazuhisa Ohe, Yuichiro |
| author2Str |
Yoshida, Tatsuya Yagishita, Shigehiro Shimoda, Yukiko Shirasawa, Masayuki Matsumoto, Yuji Masuda, Ken Shinno, Yuki Okuma, Yusuke Goto, Yasushi Horinouchi, Hidehito Yamamoto, Noboru Takahashi, Kazuhisa Ohe, Yuichiro |
| ppnlink |
ELV002331438 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.lungcan.2022.03.020 |
| up_date |
2024-07-06T23:27:27.599Z |
| _version_ |
1803874150751666176 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV057515972</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625002238.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.lungcan.2022.03.020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001751.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV057515972</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0169-5002(22)00389-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Torasawa, Masahiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• A real-world comparative study between nivolumab and pembrolizumab was conducted. • Propensity score matching was used to adjust confounding factors. • Nivolumab did not differ from pembrolizumab in efficacy and safety. • Both nivolumab and pembrolizumab are valid options for platinum-refractory PD-L1-positive NSCLC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FDA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NSCLC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">OS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IHC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DOR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IgG4</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SMD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ICI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ORR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NLR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ECOG</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TPS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD-L1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PFS</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD-1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yoshida, Tatsuya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yagishita, Shigehiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shimoda, Yukiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shirasawa, Masayuki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsumoto, Yuji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Masuda, Ken</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shinno, Yuki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Okuma, Yusuke</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goto, Yasushi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Horinouchi, Hidehito</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamamoto, Noboru</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takahashi, Kazuhisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohe, Yuichiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Garrote, Pedro J. ELSEVIER</subfield><subfield code="t">Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation</subfield><subfield code="d">2019</subfield><subfield code="d">journal of the International Association for the Study of Lung Cancer</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV002331438</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:167</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:49-57</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.lungcan.2022.03.020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">167</subfield><subfield code="j">2022</subfield><subfield code="h">49-57</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| score |
7.402338 |